Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...
In a recent editorial published in Current Pharmaceutical Analysis (Volume 18, Issue 6, 2022), researchers Dr. Behrouz Seyfinejad and Dr. Abolghasem Jouyban highlight the importance of method ...
Traditional approaches for detecting Alzheimer’s disease (AD) that rely on examining the brain for amyloid plaques have limitations in accuracy and early detection. Although the industry has ...
In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared ...
Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...
A multimodal artificial intelligence (MMAI)–derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data ...
A new draft guidance document released by the US Food and Drug Administration (FDA) aims to assist sponsors of investigational new drug applications (INDs), biologic license applications (BLAs) and ...
Patients with pancreatic cancer who have “ultra-low baseline values” of a biomarker used for prognosis have similar survival ...
This activity was supported by contracts between the National Academy of Sciences and Acadia Pharmaceuticals; Alzheimer’s Association; American Brain Coalition; American Neurological Association; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results